Mouse with D4R iRNA in the intercalating cell mass of the amygdala
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 2, 2020
Grant Date -
Mar 8, 2018
app pub date -
Mar 23, 2017
filing date -
Sep 5, 2016
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2017 Application Filing Year
- A61K Class
- 21227 Applications Filed
- 12841 Patents Issued To-Date
- 60.50 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Dec 2, 2027 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Dec 2, 2031 |
